Modulating β-lapachone release from polymer millirods through cyclodextrin complexation

Journal of Pharmaceutical Sciences

Volumn 95, Issue 10, 2006, Pages 2309-2319

  Wang, Fangjing ^a   Blanco, Elvin ^b   Ai, Hua ^c   Boothman, David A ^b   Gao, Jinming ^b  

^a Case Western Reserve University   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Cyclodextrin inclusion complexation; Drug delivery; Drug polymer interactions; Poly(lactic glycolic) acid (PLGA); lapachone

Indexed keywords

BETA LAPACHONE; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; HYDROXYPROPYL BETA CLYCLODEXTRIN; POLYGLACTIN; POLYMER; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; SCANNING ELECTRON MICROSCOPY;

EID: 33749996935     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20721     Document Type: Article

References (29)

1. LaVan DA, McGuire T, Langer R. 2003. Small-scale systems for in vivo drug delivery. Nat Biotechnol 21:1184-1191.
2. Qian F, Szymanski A, Gao J. 2001. Fabrication and characterization of controlled release poly(D, L-lactide-co-glycolide) millirods. J Biomed Mater Res 55:512-522.
3. Qian F, Nasongkla N, Gao J. 2002. Membrane-encased polymer millirods for sustained release of 5-fluorouracil. J Biomed Mater Res 61:203-211.
4. Qian F, Saidel GM, Button DM, Exner A, Gao J. 2002. Combined modeling and experimental approach for the development of dual-release polymer millirods. J Control Release 83:427-435.
5. Weinberg B, Ai H, Blanco E, Anderson J, Gao J. Antitumor efficacy and local pharmacokinetics of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res In Press.
6. Blanco E, Weinberg BD, Stowe NT, Anderson JM, Gao J. 2006. Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation. J Biomed Mater Res A 76:174-182.
7. Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, Boothman DA, Oberley LW, Cullen JJ. 2005. Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biol Ther 4:95-102.
8. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. 2000. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275:5416-5424.
9. Siegel D, Ross D. 2000. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29:246-253.
10. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA. 1995. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response. Cancer Res 55:3706-3711.
11. Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, Boothman DA. 2003. Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther 2:141-152.
12. Nasongkla N, Wiedmann AF, Bruening A, Beman M, Ray D, Bornmann WG, Boothman DA, Gao J. 2003. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res 20:1626-1633.
13. Li P, Zhao L, Yalkowsky SH. 1999. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci 88:1107-1111.
14. Rao VM, Stella VJ. 2003. When can cyclodextrins be considered for solubilization purposes? J Pharm Sci 92:927-932.
15. Loftsson T. 2002. Cyclodextrins and the biopharmaceutics classification system of drugs. J Incl Phenom Macro 44:63-67.
16. Szejtli J. 1998. Introduction and general overview of cyclodextrin chemistry. Chem Rev 98:1743-1754.
17. Singh M, Sharma R, Banerjee UC. 2002. Biotechnological applications of cyclodextrins. Biotechnol Adv 20:341-359.
18. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. 2004. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93:1804-1814.
19. Saltzman W. 2001. Drug delivery: Engineering principles for drug therapy2E New York: Oxford University Press, p 337.
20. Manosroi J, Apriyani MG, Foe K, Manosroi A. 2005. Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-beta-cyclodextrin. Int J Pharm 293:235-240.
21. Jug M, Becirevic-Lacan M. 2004. Influence of hydroxypropyl-beta- cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur J Pharm Sci 21:251-260.
22. Qian F, Stowe N, Liu EH, Saidel GM, Gao J. 2003. Quantification of in vivo doxorubicin transport from PLGA millirods in thermoablated rat livers. J Control Release 91:157-166.
23. Szymanski-Exner A, Stowe NT, Salem K, Lazebnik R, Haaga JR, Wilson DL, Gao J. 2003. Noninvasive monitoring of local drug release using X-ray computed tomography: Optimization and in vitro/in vivo validation. J Pharm Sci 92:289-296.
24. Huang X, Brazel CS. 2001. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 73:121-136.
25. von Burkersroda F, Schedl L, Gopferich A. 2002. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 23:4221-4231.
26. Wang F, Lee T, Wang CH. 2002. PEG modulated release of etanidazole from implantable PLGA/PDLA discs. Biomaterials 23:3555-3566.
27. Miyajima M, Koshika A, Okada J, Kusai A, Ikeda M. 1998. The effects of drug physico-chemical properties on release from copoly (lactic/glycolic acid) matrix. Int J Pharm 169:255-263.
28. Jang SH, Wientjes MG, Au JL. 2001. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J Pharmacol Exp Ther 296:1035-1042.
29. Strasser JF, Fung LK, Eller S, Grossman SA, Saltzman WM. 1995. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J Pharmacol Exp Ther 275:1647-1655.